Skip Navigation LinksHome > August 2014 - Volume 14 - Issue 4 > Treatment of Hymenoptera venom allergy: an update
Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0000000000000073
ANAPHYLAXIS AND INSECT ALLERGY: Edited by Jeffrey G. Demain and Gianenrico Senna

Treatment of Hymenoptera venom allergy: an update

Pesek, Robbie D.a; Lockey, Richard F.b

Collapse Box

Abstract

Purpose of review

To review and summarize the studies published between 2012 and 2014 about the use of venom immunotherapy (VIT) to treat Hymenoptera hypersensitivity.

Recent findings

Several studies reconfirm the effectiveness of VIT in both children and adults, and provide a better understanding of its immune-modulating effects. There are concerns about its cost-effectiveness; however, VIT versus self-injectable epinephrine alone when stung is the preferred treatment of choice for affected individuals when quality-of-life issues are considered. Ultrarush VIT may be as effective in children as in adults but is associated with a high risk of systemic allergic reactions (SARs). Controversy continues about the use of angiotensin-converting enzyme inhibitors and their potential for increased SARs while on VIT. Individuals with mast cell disorders, female sex, honeybee allergy, and those receiving rush or ultrarush VITs are at higher risk for SARs. Elevated baseline serum tryptase levels greater than 20 μg/l, SARs during VIT, and honeybee sensitivity are risk factors for VIT failure.

Summary

VIT remains the gold standard to treat Hymenoptera-allergic individuals to prevent future sting-induced SARs in both children and adults.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.